26
total announcements
SOLARA.NS · 15 min delayed
Solara Active Pharma Sciences Limited
Solara Active Pharma Sciences Limited has received a Rectification Order from the Assistant Commissioner of Income Tax, Central Circle 3, Thane, rectifying the error in tax computation and dropping the tax demand of Rs. 161.92 Crores raised pursuant to the Demand Notice received on March 17, 2026.
Solara Active Pharma Sciences Limited
Solara Active Pharma Sciences Limited has informed the Exchange about the completion of dispatch of 9th AGM Notice and Annual report.
Solara Active Pharma Sciences Limited
Solara Active Pharma Sciences Limited has informed the Exchange about Business Responsibility and Sustainability Report for the financial year 2025-26.
Solara Active Pharma Sciences Limited
Solara Active Pharma Sciences Limited has informed the exchange about the dispatch of Notice of Ninth Annual General Meeting (AGM) scheduled to be held on September 18, 2026, to consider and adopt the Audited Standalone Financial Statements for the financial year ended March 31, 2026, and other business.
Solara Active Pharma Sciences Limited
Solara Active Pharma Sciences Limited has informed the Stock Exchange regarding the Newspaper Publication with respect to the Ninth Annual General Meeting.
Solara Active Pharma Sciences Limited
Solara Active Pharma Sciences Limited has informed the Exchange regarding the conversion of partly paid-up Rights Equity Shares into fully paid-up equity shares in relation to the rights issue by the Company, upon receipt of the Call Monies, as applicable.
Solara Active Pharma Sciences Limited
Solara Active Pharma Sciences Limited has informed the Exchange regarding allotment of 2250 equity shares pursuant to exercise of ESOP options.
Solara Active Pharma Sciences Limited
Solara Active Pharma Sciences Limited has informed the exchange about the change in joining date/appointment date of Mr. Ajit Manocha as Chief Information Officer (CIO) and Senior Management Personnel (SMP) of the Company. The effective date of his appointment has been revised from August 10, 2026 to August 17, 2026 due to personal reasons.
Solara Active Pharma Sciences Limited
Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of Earnings conference call pertaining to financial results of the Company for the quarter ended June 30, 2026.
Solara Active Pharma Sciences Limited
Solara Active Pharma Sciences Limited has published unaudited financial results for the quarter ended June 30, 2026, through a newspaper advertisement and on its website.
Solara Active Pharma Sciences Limited
Solara Active Pharma Sciences Limited has submitted the Machine Readable copy of financial results for the quarter ended June 30, 2026, as per Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Solara Active Pharma Sciences Limited
Solara Active Pharma Sciences Limited has uploaded the audio recording of its Q1 FY27 earnings call, held on July 23, 2026, for the quarter ended June 30, 2026, on its website.
Solara Active Pharma Sciences Limited
Solara Active Pharma Sciences Limited has submitted a Monitoring Agency Report for the quarter ended June 30, 2026, regarding the utilization of proceeds from its Rights Issue. The report confirms that there has been no deviation from the objects of the issue.
Solara Active Pharma Sciences Limited
Solara Active Pharma Sciences Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32, confirming no deviation or variation in use of proceeds raised through Rights Issue. The company has utilized Rs. 333.61 crores for repayment or pre-payment of outstanding borrowings and Rs. 112.24 crores for general corporate purposes, which does not exceed 25% of the gross proceeds.
Solara Active Pharma Sciences Limited
Solara Active Pharma Sciences Limited has informed the exchange about the allotment of 2,250 equity shares to employees under the Solara Employee Stock Option Plan 2018.
Solara Active Pharma Sciences Limited
Solara Active Pharma Sciences Limited has appointed Mr. Ajit Manocha as Chief Information Officer (CIO) and Senior Management Personnel with effect from August 10, 2026.
Solara Active Pharma Sciences Limited
Solara Active Pharma Sciences Limited has reported strong Q1'27 base business performance with continued growth and profitability. The company's overall revenues stood at INR 3,843 Mn, up 20% YoY, with EBITDA at INR 635 Mn, up 10% YoY, and PAT at INR 163 Mn, marking the highest EBITDA and PAT reported over the last eighteen quarters.
Solara Active Pharma Sciences Limited
Solara Active Pharma Sciences Limited has informed the exchange about the outcome of its board meeting held on July 23, 2026, where the board considered and approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, along with the limited review report.
Solara Active Pharma Sciences Limited
Solara Active Pharma Sciences Limited has scheduled a conference call with analysts/investors to discuss its unaudited financial results for the quarter ended June 30, 2026.
Solara Active Pharma Sciences Limited
Solara Active Pharma Sciences Limited has informed the Exchange about a newspaper advertisement for a Final Reminder-cum-Forfeiture Notice for payment of Call Money to partly paid Equity shareholders.